top of page

Featured Companies

Untitled design.png

Eliksa Therapeutics

Based at the PABC in Doylestown, Eliksa Therapeutics is developing secretome-based therapies to address significant unmet needs in ocular, cardiovascular and osteoarthritic conditions. These therapies have emerged as a promising approach to overcome the traditional limitations associated with cell-based treatments. Eliksa's lead product candidate, ELK-003, is being developed to treat ocular manifestations of Epidermolysis Bullosa and entered clinical trials in 2024. 
Untitled design (1).png

Hula Therapeutics

Hula Therapeutics is dedicated to bringing safer and more efficacious therapies for children and adults with solid tumors.
Leveraging a novel target discovery engine developed at Children's Hospital of Philadelphia, the company aims to be in the clinic in late 2024 with a CAR-T cell therapy for neuroblastoma. Hula Therapeutics also is working on programs for sarcoma, medulloblastoma and gliomas. 
Untitled design (2).png

ThirdLaw Molecular LLC

ThirdLaw Molecular LLC, based in Blue Bell, Pa., is developing technologies from Temple University. The company is working to advance its Spiroligomer™ molecules as an innovative, patent-protected, new class of targeted medicines. The company’s mission is to create a revolutionary category of molecules that transform how diseases are treated more safely and effectively. 
bottom of page